Dupilumab
Sold as Dupixent. Every branded application for this active ingredient.
- First approved: Mar 28, 2017
- Branded applications: 1
- New uses approved: 19
- Complete response letters: 0
Applications
NDAs and BLAs for this ingredient, oldest first; each opens its full history| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Mar 28, 2017 | DupixentBLA 761055 · New molecular entity | Regeneron Pharmaceuticals | 32 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Drugs@FDA